Four months ago, Forus was a $1 billion startup that had just closed a $160 million Series B. On Tuesday, the three-year-old company said it had raised another $150 million at a $3 billion valuation — tripling its price tag in a single summer and pushing total equity funding past $300 million.
Bain Capital Ventures led the round, as it has since the company's seed. What is unusual is who else showed up: every existing institutional investor reinvested, the company says, including Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures and SV Angel. It was, in venture parlance, a pure insider round — the kind that signals either conviction or a lack of outside interest.
"We take it as increased conviction from our existing investors and partners in the model, in our traction and how fast we're growing," CEO and founder Sahir Jaggi told Dealroom.
Founded in 2023 and previously known as Tandem, Forus does not dispense drugs. It automates the bureaucratic no-man's-land between the moment a physician writes a prescription and the moment a patient actually takes it. Each qualifying prescription gets its own AI agent, embedded in the provider's clinical workflow, that reasons across the patient's medical record, payer coverage rules and available financial assistance to determine what happens next — prior authorization, appeals, copay cards, foundation grants, pharmacy routing. The platform is free for doctors and patients; Forus monetizes through the life sciences side of the network.
The Problem It Is Attacking
The pitch rests on a grim statistic Forus cites repeatedly: roughly one in three patients prescribed a therapy for a high-cost or complex condition never receives a first dose. Those who do often wait weeks while a practice manager faxes forms and argues with a payer's utilization management desk. The knock-on effect is clinical — physicians facing an unmanageable access process sometimes default to older, less effective drugs, or stop treating a disease area altogether. Jaggi told Fierce Healthcare that a large urology group had abandoned certain conditions because managing the associated medications had become too complex, forcing patients to seek care elsewhere.
Customers report real compression of those timelines. Family Allergy & Asthma says it cut prior authorization turnaround from more than seven days to a median of 1.1 days and reduced nursing administrative workload by 70 percent. DOCS Dermatology Group, across 140 locations, reports 80 percent more patients accessing their medications. Forus executives say the platform saves practices roughly 13 hours of administrative time per week.
"There were times a patient would come back after two or three months and tell me, 'I haven't even started the medication yet,'" said Brinda Dixit, M.D., a rheumatologist at Virginia Rheumatology Clinic in Chesapeake, Virginia, in a statement. "With Forus, approvals for these medications come back in less than two days, and patients start treatment within a week or two. My patients are getting better faster because they are getting on therapy faster."
The distribution numbers justified the markup. Forus says providers in all 50 states now use the platform to treat patients in 85 percent of U.S. residential ZIP codes. In dermatology, its launch specialty, more than a third of U.S. providers have adopted it. From there it moved into gastroenterology — including a partnership with the American Gastroenterological Association — and autoimmune disease, and is now pushing into oncology, neurology, cardiology, primary care and metabolic health. It recently expanded beyond pharmacy-benefit drugs into buy-and-bill, the messier world of physician-administered infusions.
The other half of the business is data. Because Forus sits at the choke point where prescriptions stall, it can tell drugmakers exactly where access is breaking. It now works with nine of the top 15 global biopharma companies on launch strategy, coverage and trial design.
Why It Matters
The AI-in-healthcare trade has spent three years hunting for a business model that is neither a thin EHR feature nor a regulated medical device. Forus found one in the administrative layer, where there is no FDA pathway to clear, no clinical liability to underwrite, and an enormous amount of human labor to displace.
That makes it a different animal from the direct-to-consumer pharmacy cohort — Alto, the former Capsule, Amazon Pharmacy — which competes on dispensing and delivery economics. Forus is selling orchestration, and it is giving that orchestration away to the two parties with no budget (providers and patients) while charging the one with an enormous commercial motive to see prescriptions converted (pharma).
The competitive question is whether that position holds. Cohere Health, which raised $90 million in 2025 and processes some 12 million prior authorization requests a year, attacks the same friction from the payer side. Availity, Innovaccer and a wave of a16z-backed startups are crowding in. And the market they are all chasing is real: analysts peg AI prior authorization automation at roughly $1.5 billion in 2025, growing past $10 billion by the mid-2030s.
Dealroom notes that Forus's round sits above the 95th percentile for U.S. health Series C deals all-time, alongside Latent's $80 million in March and Courier Health's $50 million in April.
"Forus is becoming how new medicine reaches people in America," said Kevin Zhang, general partner at Bain Capital Ventures, who called it one of the fastest-growing companies in the firm's portfolio. "The next era of medicine will run on the AI-powered network Forus is building."
What to Watch
Forus says it will more than double headcount this year while pushing into every specialty and care setting. Three things will determine whether the $3 billion holds: whether payers tolerate AI agents optimizing against their utilization management rules at scale; whether the biopharma revenue funding the free-to-provider model survives scrutiny about who the platform really works for; and whether a company that owns dermatology can replicate that density in oncology, where the drug costs and incumbent hub services are an order of magnitude larger.
A valuation that triples in four months prices in all three going right.
“Forus is becoming how new medicine reaches people in America. The next era of medicine will run on the AI-powered network Forus is building.”— Kevin Zhang, General Partner, Bain Capital Ventures